2 news items
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
ADAP
GLPG
30 May 24
. Combining uza-cel with Galapagos' unique decentralized manufacturing platform is a natural synergy and has the potential to deliver an even more
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
ADAP
GLPG
30 May 24
decentralized manufacturing platform is a natural synergy and has the potential to deliver an even more effective TCRÂ T-cell therapy for people
- Prev
- 1
- Next